Demcizumab
- Product Name
- Demcizumab
- CAS No.
- 1243262-17-0
- Chemical Name
- Demcizumab
- Synonyms
- OMP 21M18;Demcizumab;Demcizumab (anti-DLL4);Research Grade Demcizumab;Research Grade Demcizumab (DHJ65301)
- CBNumber
- CB48080855
- Formula Weight
- 0
- MOL File
- Mol file
Demcizumab Property
- form
- Liquid
- color
- Colorless to light yellow
Demcizumab Chemical Properties,Usage,Production
Uses
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models[1][2][3].
in vivo
Demcizumab (10 mg/kg, i.p., once a week) together with Irinotecan (7.5 mg/kg) show a significant antitumor effect in KRASWT and KRASMT CRC xenografts[2].
Demcizumab is efficacious alone or in combination with Irinotecan (7.5 mg/kg) in OMP-C8 colon tumors[3].
Demcizumab (20 mg/kg/week, i.p.) increases mice survival in irradiated NRG mice injected PDTALL13 cells[4].
| Animal Model: | KRASWT and KRASMT CRC xenografts[2] |
| Dosage: | 10 mg/kg, together with Irinotecan (HY-16562) (7.5 mg/kg) |
| Administration: | Intraperitoneal injection (i.p.), once a week |
| Result: | Resulted in tumor regression at day 20. |
References
[1] Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. DOI:10.1158/1078-0432.CCR-14-1373
[2] Fischer?M, et al.?Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res?2011;71:1520-5. DOI:10.1158/0008-5472.CAN-10-2817
[3] Hoey?T, et al.?DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell?2009;5:168–77. DOI:10.1016/j.stem.2009.05.019
[4] Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608. DOI:10.7150/thno.48067
Demcizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Demcizumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58